Skip to main content
← All trials
TMJ PainPainDental and oral healthDrugPhase 3

What this study is

The goal of this clinical trial is to evaluate the efficacy of topical 2.5% hydrocortisone in TMJ arthralgia. The main questions it aims to answer are:

  • How does pain reduction compare?
  • How does improvement in jaw function limitation compare?
  • How do side effects compare? Participants will
  • On day 1 be examined and report their pain level and jaw function limitation
  • On days 1-21, apply their cream four times a day
  • On day 21, report their pain level, jaw function limitation, compliance with instructions, and side effects.

Researchers will compare topical 2.5% hydrocortisone and topical 1% diclofenac to see if efficacy and side effects differ.

What's being tested

  • Hydrocortisone 2.5%

    Intervention · DRUG

  • Diclofenac 1% topical

    Intervention · DRUG

Both interventions

Applied four times daily to TMJ with arthralgia

Study details

Official title
Comparison of Topical 1% Diclofenac and Topical 2.5% Hydrocortisone for TMJ Arthralgia
Sponsor
University of the Pacific
Conditions
TMJ Pain
Enrolling
90 people
Starts
2023-06-01
Est. completion
2026-04
Design
Quadruple-blind, randomized, parallel groups, Phase 3
Record
View on ClinicalTrials.gov ↗